approv
antivir
therapeut
select
inhibit
protein
encod
singl
viru
therebi
provid
one
drugon
bug
solut
result
narrow
spectrum
coverag
high
cost
drug
develop
therapi
current
approv
fewer
ten
virus
hundr
known
caus
human
diseas
perspect
summar
progress
challeng
develop
broadspectrum
antivir
therapi
strategi
includ
target
enzymat
function
share
multipl
virus
host
cell
machineri
newli
discov
compound
repurpos
approv
drug
approach
offer
new
practic
mean
develop
therapeut
exist
emerg
viral
threat
although
hundr
virus
known
caus
human
diseas
antivir
therapi
approv
fewer
ten
approv
antivir
drug
target
viral
enzym
commonli
proteas
polymeras
direct
act
antivir
daa
shown
consider
success
treatment
hiv
hepat
c
viru
hcv
infect
howev
approach
scale
easili
limit
particularli
respect
emerg
reemerg
virus
vaccin
antivir
therapi
approv
major
limit
commonli
develop
daa
narrow
spectrum
coverag
rang
singl
viral
genotyp
sever
relat
virus
given
averag
cost
two
billion
dollar
timelin
develop
new
drug
target
virus
individu
make
drug
develop
expens
slow
moreov
given
unpredict
natur
viru
emerg
approach
provid
adequ
global
health
protect
nation
secur
prepared
final
resist
convent
daa
typic
emerg
rapidli
issu
partli
circumv
combin
drug
treatment
drugdrug
interact
cumul
toxic
often
complic
strategi
emerg
reemerg
pathogen
specif
licens
treatment
exist
includ
flaviviru
dengu
estim
infect
million
peopl
annual
coronavirus
sarscov
merscov
associ
outbreak
respect
filoviru
ebola
respons
current
largescal
epidem
africa
urgent
need
novel
drug
mani
viral
diseas
need
unlik
met
sole
prevail
drugdevelop
approach
broadspectrum
drug
play
role
address
need
see
figur
drastic
reduc
time
cost
associ
earli
stage
drug
develop
per
approv
indic
diminish
clinic
risk
advanc
phase
offlabel
use
approv
broadspectrum
antivir
new
viral
indic
provid
econom
incent
well
facilit
readi
futur
outbreak
emerg
pathogen
broadspectrum
therapeut
could
also
administ
viral
threat
accur
diagnos
increas
likelihood
viral
control
concept
broadspectrum
antivir
first
introduc
one
earliest
broadspectrum
antivir
agent
ribavirin
inhibit
viral
dna
rna
synthesi
us
ribavarin
approv
treatment
hcv
respiratori
syncyti
viru
although
ribavirin
report
benefit
resolut
mani
emerg
viral
infect
preclin
yield
margin
benefit
clinic
ribavirin
today
administ
togeth
interferon
solubl
immun
factor
activ
vertebrateinfect
virus
approv
hcv
treatment
howev
interferon
treatment
shown
partial
success
rate
requir
intramuscular
inject
seriou
side
effect
expens
promis
nextgener
nucleotid
nucleosid
analogu
recent
develop
exampl
synthet
adenosin
analog
inhibit
replic
rna
virus
nine
famili
includ
coronavirus
flavivirus
vitro
anim
model
protect
nonhuman
primat
filoviru
diseas
favor
preliminari
preclin
safeti
profil
favipiravir
anoth
nucleosid
analogu
also
vitro
vivo
efficaci
sever
rna
viral
famili
human
trial
treatment
influenza
ebola
ongo
brincidofovir
lipid
conjug
nucleotid
analogu
cidofovir
show
vitro
activ
multipl
dna
virus
includ
herpesvirus
papillomaviru
favor
pharmacokinet
profil
advanc
phase
iii
trial
howev
extens
sequenc
structur
divers
viral
encod
protein
design
broadspectrum
daa
seldom
feasibl
thu
far
one
class
molecul
nucleosid
inhibitor
shown
promis
clinic
differ
broadspectrum
antivir
strategi
target
host
host
protein
pathway
requir
multipl
virus
attract
target
broadspectrum
antivir
often
ad
benefit
higher
genet
barrier
resist
clinic
advanc
repres
class
cyclophilin
inhibitor
alisporivir
compound
act
multifacet
way
includ
impair
protein
fold
augment
innat
immun
respons
inhibit
divers
group
rna
dna
virus
includ
hcv
dengu
viru
hiv
influenza
sarscov
vitro
anim
model
shown
promis
antihcv
drug
phase
iiiii
trial
er
anoth
host
protein
serv
broadspectrum
antivir
target
glycoprotein
mani
envelop
virus
depend
host
glucosidas
achiev
proper
fold
iminosugar
celgosivir
competit
substrat
bekerman
activ
multipl
unrel
virus
tissu
cultur
rodent
littl
efficaci
found
thu
far
celgosivir
clinic
studi
investig
glucosidas
inhibitor
warrant
repurpos
approv
drug
target
host
function
requir
sever
virus
costand
timeeffect
rout
broadspectrum
antivir
one
area
investig
target
host
factor
involv
regul
intracellular
viral
traffick
exampl
host
kinas
cyclin
g
associ
kinas
gak
protein
kinas
regul
viral
traffick
entri
assembl
releas
unrel
virus
approv
anticanc
drug
erlotinib
sunitinib
potent
inhibit
gak
respect
show
vitro
activ
hcv
sever
flavivirus
ebola
viru
hiv
combin
erlotinib
sunitinib
protect
mice
lethal
dengu
ebola
viru
challeng
advanc
clinic
trial
dengu
ebola
kinas
inhibitor
dasatinib
imatinib
nilotinib
addit
approv
anticanc
drug
broad
antivir
activ
anoth
drug
may
repurpos
nitazoxanid
fdaapprov
treatment
parasit
diarrhea
inhibit
replic
respiratori
virus
hiv
hcv
flavivirus
virus
reduc
durat
flu
symptom
clinic
studi
nitazoxanid
block
matur
influenza
hemagglutinin
target
remain
unknown
approv
drug
whose
therapeut
potenti
emerg
virus
evalu
includ
chloroquin
antimalari
agent
atorvastatin
alter
host
lipid
metabol
focus
host
function
use
expans
potenti
antivir
drug
target
approach
face
challeng
cellular
protein
function
complex
network
interact
complet
understand
drug
mechan
action
often
elus
moreov
achiev
invitro
phenotyp
often
translat
invivo
outcom
toxic
anoth
major
concern
nevertheless
may
feasibl
identifi
therapeut
window
drug
level
suffici
inhibit
viral
replic
minim
cellular
toxic
furthermor
shift
indic
requir
longterm
therapi
eg
month
year
cancer
shorter
durat
suffici
treat
acut
viral
infect
help
limit
toxic
emerg
resist
typic
daa
monotherapi
also
complic
treatment
hosttarget
approach
case
antagonist
maraviroc
nevertheless
time
resist
hosttarget
approach
appear
longer
level
resist
lower
daa
exemplifi
treatment
cyclophilin
inhibitor
taken
togeth
meet
clinic
need
present
emerg
virus
best
achiev
combinatori
approach
includ
discoveri
novel
broadli
act
daa
hosttarget
therapi
well
repurpos
alreadi
approv
drug
antivir
drug
select
inhibit
uniqu
viral
protein
provid
one
drug
one
bug
solut
broadspectrum
drug
restrict
multipl
virus
inhibit
either
common
viral
enzymat
function
host
factor
commonli
requir
sever
virus
lower
panel
depict
specif
stage
viral
life
cycl
blue
rectangl
often
target
class
drug
specif
exampl
broadspectrum
compound
denot
orang
correspond
target
protein
pathway
grey
cypa
cyclophilin
